Indications for BAT:
Symptomatic botulism following exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G.
See full labeling. Administer as slow IV infusion. ≥17yrs: give 1 vial at a rate of 0.5mL/min for first 30mins; double the rate every 30mins if tolerated; max rate 2mL/min. Risk for hypersensitivity reaction: start at lowest rate possible (<0.01mL/min); monitor.
See full labeling. Calculate dose by body wt based on Salisbury Rule. Administer as slow IV infusion. <1yr: give 10% of adult dose at a rate of 0.01mL/kg/min for first 30mins; increase in 0.01mL/kg/min every 30mins if tolerated; max rate 0.03mL/kg/min. 1–<17yrs: give 20–100% of adult dose at a rate of 0.01mL/kg/min for first 30mins; increase in 0.01mL/kg/min every 30mins if tolerated; max rate 0.03mL/kg/min (not to exceed adult rate). Risk for hypersensitivity reaction: start at lowest rate possible (<0.01mL/min); monitor.
Increased risk for severe hypersensitivity reactions if previous therapy with equine-derived antivenom/antitoxin, history of hypersensitivity to horses, asthma, or hay fever. Have appropriate equipment, medication (including epinephrine), and trained personnel readily available. Monitor for acute allergic reaction during and after infusion; discontinue immediately if hypersensitivity reactions occur. Monitor for delayed allergic reactions (serum sickness), vital signs during infusion. Reduce infusion rate if infusion-related reactions occur; discontinue if symptoms worsen. Contains equine plasma; risk of viral transmission. Elderly. Pregnancy. Nursing mothers.
Maltose content: may interfere with certain blood glucose monitoring systems and can result in falsely elevated glucose readings; use test systems that are glucose-specific.
Headache, nausea, pruritus, urticaria, pyrexia, rash, chills, edema; hemodynamic instability (eg, tachycardia, bradycardia, asystole), hypersensitivity reactions, serum sickness.
Generic Drug Availability:
Single-dose vial (20mL, 50mL)—1